Compare · MEDP vs MXCT
MEDP vs MXCT
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and MaxCyte Inc. (MXCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and MXCT operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $17.14B, about 123.0x MXCT ($139.3M).
- MEDP has been more active in the news (10 items in the past 4 weeks vs 4 for MXCT).
- MEDP has more recent analyst coverage (25 ratings vs 11 for MXCT).
- Company
- Medpace Holdings Inc.
- MaxCyte Inc.
- Price
- -
- -
- Market cap
- $17.14B
- $139.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2021
- News (4w)
- 10
- 4
- Recent ratings
- 25
- 11
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
MaxCyte Inc.
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Latest MEDP
- President & CEO Troendle August J. sold $9,969,094 worth of shares (15,978 units at $623.93), decreasing direct ownership by 3% to 545,217 units (SEC Form 4)
- CFO & Treasurer Brady Kevin M. exercised 3,400 shares at a strike of $138.87 and sold $2,125,816 worth of shares (3,400 units at $625.24) (SEC Form 4)
- President & CEO Troendle August J. sold $26,281,390 worth of shares (42,783 units at $614.30), decreasing direct ownership by 7% to 561,195 units (SEC Form 4)
- Director Carley Brian T sold $3,043,150 worth of shares (5,000 units at $608.63), decreasing direct ownership by 15% to 27,825 units (SEC Form 4)
- Director Davenport Fred B Jr exercised 7,583 shares at a strike of $116.08 and sold $4,414,590 worth of shares (7,283 units at $606.15), increasing direct ownership by 9% to 3,798 units (SEC Form 4)
- SEC Form 144 filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $7,111,969 worth of shares (11,824 units at $601.49), decreasing direct ownership by 2% to 603,978 units (SEC Form 4)
- Director Mccarthy Cornelius P. Iii sold $690,122 worth of shares (1,140 units at $605.37), decreasing direct ownership by 8% to 12,275 units (SEC Form 4)
- President & CEO Troendle August J. sold $13,984,854 worth of shares (23,144 units at $604.25), decreasing direct ownership by 4% to 615,802 units (SEC Form 4)
- Director Mccarthy Cornelius P. Iii exercised 3,858 shares at a strike of $84.36 and sold $465,131 worth of shares (795 units at $585.07), increasing direct ownership by 30% to 13,415 units (SEC Form 4)
Latest MXCT
- MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
- SEC Form 10-Q filed by MaxCyte Inc.
- MaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- MaxCyte Reports Second Quarter 2026 Financial Results
- MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
- MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
- Director Johnston John Joseph was granted 30,421 shares, increasing direct ownership by 18% to 201,581 units (SEC Form 4)
- Director Hemrajani Rekha was granted 30,421 shares, increasing direct ownership by 76% to 70,314 units (SEC Form 4)
- Director Erck Stanley C was granted 30,421 shares, increasing direct ownership by 8% to 428,749 units (SEC Form 4)
- Director Douglas Richard was granted 30,421 shares, increasing direct ownership by 13% to 260,998 units (SEC Form 4)